News from Monday, October 28, 2024
Articles
PhRMA: HRSA's Pushback Against Drug Maker Policies Permits Program Exploitation
(10/25, Gabrielle Wanneh, InsideHealthPolicy) reports “...The brand drug lobby is calling on Congress to pass legislation that would demand more transparency from hospitals and community health centers participating in the 340B drug discount program and curb statutory violations following the government's success in getting Johnson & Johnson to cease implementation of a policy that would have paid a rebate to certain covered entities for select 340B drugs instead of the traditional upfront discount.” Subscription Required
Cross-Country HTA Collaboration To Focus On Health Economics & RWE
(10/28, Francesca Bruce, Pink Sheet) reports “...European cross-country HTA collaborations have much to learn from each other to keep drug prices from rising unfairly, Nordic health technology assessment experts say, adding that talks on collaboration are also ongoing with HTA bodies outside the continent.” Subscription Required
Press Releases
Lewis Katz School of Medicine at Temple University Awarded Nearly $1 Million in PCORI Funding to Improve Antibiotic Prescribing for Childhood Respiratory Infections
(10/28, Temple University Health System Press Release) “A team at the Lewis Katz School of Medicine at Temple University, part of Temple Health, has been awarded nearly $1 million by the Patient-Centered Outcomes Research Institute (PCORI) to help improve antibiotic prescribing for children with acute respiratory tract infections.” Full
New Research and Methodological Innovations Presented by Target RWE at DIA RWE 2024
(10/28, Target RWE Press Release) “...‘Our presentations underscore Target RWE's pivotal role in pioneering innovative methodologies that significantly enhance study performance while effectively mitigating potential biases,’ said Chief Scientific Officer, Jennifer Christian, PharmD, PhD, FISPE. ‘As a company, we are committed to advancing drug development by conducting robust real world evidence studies that measure and evaluate meaningful patient outcomes and tackle the complexities of real-world data.’” Full
Journals
Inhaled Reliever Therapies for Asthma: A Systematic Review and Meta-Analysis
Daniel G. Rayner, MSc; Dario M. Ferri, MD; Gordon H. Guyatt, MD; et al
October 28, 2024, JAMA